T2807
Thymidine Phosphorylase, recombinant from Escherichia coli
recombinant, expressed in E. coli, buffered aqueous solution, ≥500 units/mL
Sinónimos:
Thymidine:orthophosphate deoxy-D-ribosyltransferase
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Número de CAS:
Número MDL:
Código UNSPSC:
12352204
NACRES:
NA.54
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Productos recomendados
recombinante
expressed in E. coli
Nivel de calidad
Formulario
buffered aqueous solution
concentración
≥500 units/mL
Nº de acceso UniProt
temp. de almacenamiento
2-8°C
Información sobre el gen
Escherichia coli K12 ... deoA(948901)
¿Está buscando productos similares? Visita Guía de comparación de productos
Descripción general
Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation. [1]
Aplicación
Thymidine phosphorylase has been used in a study to assess TAS-102 treatment in patients with advanced solid tumors. [2] Thymidine phosphorylase has also been used in a study to investigate antitumor effects of the FP3 protein on patient-derived tumor tissue xenograft models of primary colon carcinoma. [3]
Acciones bioquímicas o fisiológicas
An enzyme that catalyzes the reversible conversion of thymidine to thymine. Thymidine phosphorylase is part of the pyrimidine nucleoside salvage pathway.
An enzyme that catalyzes the reversible conversion of thymidine to thymine. Thymidine phosphorylase is part of the pyrimidine nucleoside salvage pathway. This pathway allows pyrimidine bases to be recycled for nucleotide biosynthesis, while the pentose 1-phosphates are converted to intermediates of the pentose phosphate shunt and glycolysis. The E. coli thymidine phosphorylase shares 40% sequence homology with the human sequence, which has been found to be identical to the angiogenic agent platelet-derived endothelial growth factor. The purified E. coli enzyme has been shown to stimulate blood vessel growth in chick chorioallantoic membrane assays.
Definición de unidad
One unit will convert 1.0 μmole each of thymidine and phosphate to thymine and 2-deoxyribose 1-phosphate per min at pH 7.4 at 25°C.
Forma física
Solution in 0.5 M potassium phosphate containing 2 mM uracil, 0.02% sodium azide and bovine serum albumin
Nota de preparación
Cloned from E. coli and produced in overexpressing E. coli
Código de clase de almacenamiento
12 - Non Combustible Liquids
Clase de riesgo para el agua (WGK)
WGK 2
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Equipo de protección personal
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
¿No ve la versión correcta?
Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Charlotte Gasson et al.
Journal of pharmaceutical and biomedical analysis, 72, 16-24 (2012-11-14)
Erythrocyte encapsulated thymidine phosphorylase (EE-TP) is under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a fatal metabolic disorder resulting from an inherited deficiency of the enzyme thymidine phosphorylase. We report here the development and validation of
T Doi et al.
British journal of cancer, 107(3), 429-434 (2012-06-28)
TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. TAS-102 was administered twice daily on days 1-5 and days 8-12 in
Domenico Ribatti et al.
Expert opinion on therapeutic targets, 16(12), 1215-1225 (2012-09-18)
Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help
Jian Zhang et al.
Cancer chemotherapy and pharmacology, 71(1), 103-113 (2012-10-12)
The difference between combinational and pre-planned sequential therapies using regimens that include non-anthracycline and taxane in the first-line setting remains unclear. The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer
Michelle Levene et al.
Toxicological sciences : an official journal of the Society of Toxicology, 131(1), 311-324 (2012-09-15)
Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is currently under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), an autosomal recessive disorder caused by a deficiency of thymidine phosphorylase. The rationale for the development of EE-TP is based on the
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
